Definition of new pharmacophores for nonpeptide antagonists of human urotensin-II. Comparison with the 3D-structure of human urotensin-II and URP

Journal of Chemical Information and Modeling

Volumn 47, Issue 2, 2007, Pages 602-612

  Lescot, Elodie ^a   Santos, Jana Sopkova De Oliveira ^a   Dubessy, Christophe ^b   Oulyadi, Hassan ^b   Lesnard, Aurélien ^a   Vaudry, Hubert ^b   Bureau, Ronan ^a   Rault, Sylvain ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONFORMATIONS; DISEASES; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDES; THREE DIMENSIONAL;

3D STRUCTURES; CONFORMATION FLEXIBILITIES; MICROMOLAR AFFINITIES; PHARMACOPHORES;

DRUG PRODUCTS;

AMIDE; PEPTIDE; PROTON; UROTENSIN; UROTENSIN II;

ARTICLE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE; THREE DIMENSIONAL IMAGING;

AMIDES; COMPUTATIONAL BIOLOGY; HUMANS; IMAGING, THREE-DIMENSIONAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDES; PROTONS; UROTENSINS;

EID: 34247244635     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci6003948     Document Type: Conference Paper

References (59)

1. Pearson, D.; Shively, J. E.; Clark, B. R.; Geschwind, I.; Barkley, M.; Nishioka, R. S.; Bern, H. A. Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 5021-5024.
2. Coulouarn, Y.; Lihrmann, I.; Jegou, S.; Anouar, Y.; Tostivint, H.; Beauvillain, J. C.; Conlon, J. M.; Bern, H. A.; Vaudry, H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15803-15808.
3. Ames, R. S.; Sarau, H. M.; Chambers, J. K.; Willette, R. N.; Aiyar, N. V.; Romanic, A. M.; Louden, C. S.; Foley, J. J.; Sauermelch, C. F.; Coatney, R. W.; Ao, Z.; Disa, J.; Holmes, S. D.; Stadel, J. M.; Martin, J. D.; Liu, W. S.; Glover, G. I.; Wilson, S.; McNulty, D. E.; Ellis, C. E.; Elshourbagy, N. A.; Shabon, U.; Trill, J. J.; Hay, D. W.; Ohlstein, E. H.; Bergsma, D. J.; Douglas, S. A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401, 282-286.
4. MacLean, M. R.; Alexander, D.; Stirrat, A.; Gallagher, M.; Douglas, S. A.; Ohlstein, E. H.; Morecroft, I.; Polland, K. Contractile responses to human urotensin-II in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol. 2000, 130, 201-204.
5. Maguire, J. J.; Davenport, A. P. Is urotensin-II the new endothelin? Br. J. Pharmacol. 2002, 137, 579-588.
6. Douglas, S. A.; Ohlstein, E. H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med. 2000, 10, 229-237.
7. Ong, K. L.; Lam, K. S.; Cheung, B. M. Urotensin II: Its function in health and its role in disease. Cardiovasc. Drugs Ther. 2005, 19, 65-75.
8. Matsushita, M.; Shichiri, M.; Imai, T.; Iwashina, M.; Tanaka, H.; Takasu, N.; Hirata, Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens. 2001, 19, 2185-2190.
9. Totsune, K.; Takahashi, K.; Arihara, Z.; Sone, M.; Ito, S.; Murakami, O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. (London) 2003, 104, 1-5.
10. Totsune, K.; Takahashi, K.; Arihara, Z.; Sone, M.; Satoh, F.; Ito, S.; Kimura, Y.; Sasano, H.; Murakami, O. Role of urotensin II in patients on dialysis. Lancet 2001, 358, 810-811.
11. Sugo, T.; Murakami, Y.; Shimomura, Y.; Harada, M.; Abe, M.; Ishibashi, Y.; Kitada, C.; Miyajima, N.; Suzuki, N.; Mon, M.; Fujino, M. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem. Biophys. Res. Commun. 2003, 310, 860-880.
12. Bousette, N.; Patel, L.; Douglas, S. A.; Ohlstein, E. H.; Giaid, A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004, 176, 117-123.
13. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
14. Kinney, W. A.; Almond, H. R., Jr.; Qi, J.; Smith, C. E.; Santulli, R. J.; de Garavilla, L.; Andrade-Gordon, P.; Cho, D. S.; Everson, A. M.; Feinstein, M. A.; Leung, P. A.; Maryanoff, B. E. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew. Chem., Int. Ed. 2002, 41, 2940-2944.
15. Grieco, P.; Carotenuto, A.; Campiglia, P.; Zampelli, E.; Patacchini, R.; Maggi, C. A.; Novellino, E.; Rovero, P. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J. Med. Chem. 2002, 45, 4391-4394.
16. Chatenet, D.; Dubessy, C.; Leprince, J.; Boularan, C.; Carlier, L.; Segalas-Milazzo, I.; Guilhaudis, L.; Oulyadi, H.; Davoust, D.; Scalbert, E.; Pfeiffer, B.; Renard, P.; Tonon, M. C.; Lihrmann, I.; Pacaud, P.; Vaudry, H. Structure - activity relationships and structural conformation of a novel urotensin II-related peptide. Peptide 2004, 25, 1819-1830.
17. Aissaoui, H.; Binkert, C.; Clozel, M.; Mathys, B.; Mueller, C.; Nayler, O.; Scherz, M.; Velker, J.; Weller, T. Preparation of l-(piperazinylalkyl)-3- quinolinylurea derivatives as urotensin II antagonists. PCT Int. Appl. 2004, WO 2004099179, 63.
18. Aissaoui, H.; Binkert, C.; Clozel, M.; Mathys, B.; Mueller, C.; Nayler, O.; Scherz, M.; Verker, J.; Weller, T. Preparation of novel piperidine derivatives as urotensin II antagonists. PCT Int. Appl. 2004, WO 2004099180, 32.
19. Aissaoui, H.; Binkert, C.; Clozel, M.; Mathys, B.; Mueller, C.; Nayler, O.; Scherz, M.; Weller, T. Preparation of 1,2,3,4-tetrahydroisoquinolinyl ureas and related derivatives as urotensin II receptor antagonists. PCT Int. Appl. 2002, WO 2002076979, 94.
20. Mathys, B.; Mueller, C.; Scherz, M.; Weller, T.; Clozel, M.; Velker, J.; Bur, D. Preparation of pyridinyl ureas as urotensin II antagonists. PCT Int. Appl. 2005, WO2005030209, 113.
21. Kikkawa, H.; Kushida, H. Sulfonamides, and pharmaceutical compositions containing them, for the treatment of inflammatory bowel diseases. PCT Int. Appl. 2005, WO2005072226, 19.
22. Clozel, M.; Binkert, C.; Birker-Robaczewska, M.; Boukhadra, C.; Ding, S. S.; Fischli, W.; Hess, P.; Mathys, B.; Morrison, K.; Muller, C.; Muller, C.; Nayler, O.; Qiu, C.; Rey, M.; Scherz, M. W.; Velker, J.; Weller, T.; Xi, J. F.; Ziltener, P. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)-ethyl]-3-(2-methyl- quinolin-4-yl)-urea sulfate salt): First demonstration of a pathophysiological role of the urotensin system. J. Pharmacol. Exp. Ther. 2004, 311, 204-212.
23. Tarui, N.; Santo, T.; Watanabe, H.; Aso, K.; Ishihara, Y. Preparation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives as GPR14 antagonists. PCT Int. Appl. 2002, WO 2002002530, 217.
24. Tarui, N.; Santo, T.; Watanabe, H.; Aso, K.; Miwa, T.; Takekawa, S. Preparation of biphenylcarboxamide compounds as GPR14 antagonists or somatostatin receptor regulators. PCT Int. Appl. 2002, WO 2002000606, 274.
25. Tarui, N.; Santo, T.; Mori, M.; Watanabe, H. Quinoline derivatives as vasoactive agents exhibiting orphan receptor GPR14 protein antagonism. PCT Int. Appl. 2001, WO 2001066143, 97.
26. Jin, J.; Dhanak, D.; Knight, S. D.; Widdowson, K.; Aiyar, N.; Naselsky, D.; Sarau, H. M.; Foley, J. J.; Schmidt, D. B.; Bennett, C. D.; Wang, B.; Warren, G. L.; Moore, M. L.; Keenan, R. M.; Rivero, R. A.; Douglas, S. A. Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 3229-3232.
27. Dhanak, D.; Knight, S. D. Sulfonamide derivative urotensin-II receptor antagonists, preparation, pharmaceutical compositions, and therapeutic use. PCT Int. Appl. 2001, WO2001045694, 40.
28. Dodson, J. W.; Ghavimi-Alagha, B.; Girard, G. R.; King, B. W.; McAtee, J. J.; Neeb, M. J.; Wang, N.; Yuan, C. C. K. Preparation of sulfonamides as antagonists of urotensin II. PCT Int. Appl. 2004, WO2004043366, 82.
29. Barton, L. S.; Dodson, J. W.; Gaitanopoulos, D. E.; Girard, G. R.; King, B. W.; McAtee, J. J.; Neeb, M. J. Preparation of sulfonamides as antagonists of urotensin II. PCT Int. Appl. 2004, WO2004043917, 81.
30. Dhanak, D.; Gallagher, T. F.; Knight, S. D.; Schmidt, S. J. Preparation of sulfonamides as antagonists of urotensin II. PCT Int. Appl. 2002, WO2002089785, 35.
31. Dhanak, D.; Knight, S. D.; Jin, J.; Rivero, R. A. Preparation of pyrrolidine sulfonamides as urotensin II antagonists. PCT Int. Appl. 2002, WO2002078641, 19.
32. Dhanak, D.; Knight, S. D. Preparation of quinolones as urotensin-II receptor antagonists. PCT Int. Appl. 2002, WO2002047456, 16.
33. Croston, G. E.; Olsson, R.; Currier, E. A.; Burstein, E. S.; Weiner, D.; Nash, N.; Severance, D.; Allenmark, S. G.; Thunberg, L.; Ma, J. N.; Mohell, N.; O'Dowd, B.; Brann, M. R.; Hacksell, U. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-(dimethylamino) ethyl) isochroman-1-one (AC-7954). J. Med. Chem. 2002, 45, 4950-4953.
34. Olsson, R. A combinatorial scaffold approach towards the pharmacophores of ligands to urotensin II and somatostatin 5 receptors. PCT Int Appl. 2004, WO 2004073642, 29.
35. Carotenuto, A.; Grieco, P.; Campiglia, P.; Novellino, E.; Rovero, P. Unraveling the active conformation of urotensin II. J. Med. Chem. 2004, 47, 1652-1661.
36. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; Sates, D. J.; Swaninathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
37. Smellie, A.; Teig, S. L.; Towin, P. Poling: Promoting conformational variation. J. Comput. Chem. 1995, 16, 171-187.
38. States, D. J.; Haberkorn, R. A.; Ruben, D. J. A two-dimensional nuclear Overhauser effect experiment with pure absorption phase in four quadrants. J. Magn. Reson. 1982, 48, 286-292.
39. Sklenar, V.; Piotto, M.; Leppik, R.; Saudek, V. Gradient-tailored water suppression for 1H-15N HSQC experiments optimized to retain full sensitivity. J. Magn. Reson. 1933, 102, 241-245.
40. Aue, W. P.; Bartholdi, E.; Ernst, R. R. Two-dimensional spectroscopy, Application to Nuclear Magnetic Resonance. J. Chem. Phys. 1976, 64, 2229-2246.
41. Braunschweiler, L.; Ernst, R. R. Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy. J. Magn. Reson. 1983, 53, 521-528.
42. Jeener, J.; Meier, B. H.; Bachmann, P.; Ernst, R. R. Investigation of exchange process by two-dimensional NMR spectroscopy. J. Chem. Phys. 1979, 71, 4546-4553.
43. Kumar, A,; Ernst, R. R.; Wuthrich, K. A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. Biochem. Biophys. Res. Commun. 1980, 95, 1-6.
44. α for identification of helical secondary structure. J. Mol. Biol. 1984, 180, 741-751.
45. Nilges, M.; Gronenborn, A. M.; Brunger, A. T.; Clore, G. M. Determination of three-dimensional structures of proteins by simulated annealing with interproton distance restraints. Application to crambin, potato carboxypeptidase inhibitor and barley serine proteinase inhibitor 2. Protein Eng. 1988, 2, 27-38.
46. MacKerell, J. A. D.; Bashford, D.; Bellott, M.; Dunbrack, J. R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, I. W. E.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 1988, 102, 3586-3616.
47. Jorgensen, W. L.; Chandrashekar, J.; Madura, J. D.; Impey, R.; Klein, M. L. Refined TIP3P model for water. J. Chem. Phys. 1983, 79, 926-935.
48. Dubs, A.; Wagner, G.; Wuthrich, K. Individual assignments of amide proton resonances in the proton NMR spectrum of the basic pancreatic trypsin inhibitor. Biochim. Biophys. Acta 1979, 577, 177-194.
49. 1H nuclear-magnetic-resonance techniques for studies of proteins. Eur. J. Biochem. 1981, 114, 375-384.
50. Wüthrich, K.; Billeter, M.; Braun, W. Polypeptide secondary structure determination by nuclear magnetic resonance observation of short proton-proton distances. J. Mol. Biol. 1984, 180, 715-740.
51. Wüthrich, K., In NMR of Proteins and Nucleic Acids; Wiley: New York, 1986.
52. Wagner, G.; Wüthrich, K. Sequential resonance assignments in protein 'H nuclear magnetic resonance spectra: Basic pancreatic trypsin inhibitor. J. Mol. Biol. 1982, 155, 347-366.
53. Englander, S. W.; Kallenbach, N. R. Hydrogen exchange and structural dynamics of proteins and nucleic acids. Q. Rev. Biophys. 1984, 16, 521-665.
54. Wagner, G.; Wüthrich, K. Amide protein exchange and surface conformation of the basic pancreatic trypsin inhibitor in solution. Studies with two-dimensional nuclear magnetic resonance. J. Mot. Biol. 1982, 160, 343-361.
55. 1H NMR assignments and secondary structure of hen egg white lysozyme in solution. Biochemistry 1988, 27, 122-136.
56. Wagner, G. Characterization of the distribution of internal motions in the basic pancreatic trypsin inhibitor using a large number of internal NMR probes. Q. Rev. Biophys. 1983, 16, 1-57.
57. Wüthrich, K.; Wider, G.; Wagner, G.; Braun, W. Sequential resonance assignments as a basis for determination of spatial protein structures by high resolution proton nuclear magnetic resonance. J. Mol. Biol. 1982, 155, 311-319.
58. Csizmadia, F. JChem: Java applets and modules supporting chemical database handling from web browsers. J. Chem. Inf. Comput. Sci. 2000, 40, 323-324.
59. Lavecchia, A.; Cosconati, S.; Novellino, E. Architecture of the human urotensin II receptor: Comparison of the binding domains of peptide and non-peptide urotensin II agonists. J. Med. Chem. 2005, 48, 2480-2492.